To print: Select File and then Print from your browser's menu

Title: New Agonist, Almotriptan Effective for Migraine

URL: http://www.blackwell-synergy.com/servlet/useragent?func=synergy&
&synergyAction=showAbstract&doi=10.1046/j.1468-2982.2002.00394.x

Cephalalgia Volume 22 Issue 6 Page 453 - July 2002. "Almotriptan is an effective and well-tolerated treatment for migraine pain: results of a randomized, double-blind, placebo-controlled clinical trial"
08/14/2002 09:04:00 AM
By Harvey McConnell

The new, specific 5-HT[_1B/1D agonist almotriptan is an effective and well-tolerated treatment for migraine pain according to a new randomised, single-dose, double-blind study. The multicentre trial compared almotriptan with sumatriptan among a cohort of 668 patients treated at Kings College Hospital, London, England; Hôpital Saint-Antoine-Service de Neurologie, Paris, France; and Hospital General de Valencia, Valencia, Spain. Clinicians treated a single migraine attack of moderate or severe intensity in each patient with either oral almotriptan, at 12.5 mg and 25 mg, or sumatriptan 100 mg- the current standard treatment for migraine, or placebo. Primary efficacy was assessed of migraine pain relief, and with improvement from severe or moderate pain to mild or no pain, at two hours following treatment. Clinicians calculated response rates among the patients, which were stratified for variation in baseline pain levels, and found both almotriptan doses were equivalent to sumatriptan and significantly better than placebo. In addition, other assessments they used of efficacy confirmed the equivalence of the almotriptan groups with the sumatriptan group. Among the patients the overall incidence of adverse events showed that almotriptan at a dosage of 12.5 mg was as well tolerated as placebo (p=0.493), and significantly better tolerated than sumatriptan (p<0.001). There was no statistically significant difference in the incidence of adverse events between almotriptan 25 mg dosage and sumatriptan 100 mg dosage (p=0.376). The results from this large clinical study indicate that the new, specific 5-HT_1B/1D agonist, almotriptan, is an effective and well-tolerated treatment for migraine pain, the clinicians concluded.

http://www.blackwell-synergy.com/servlet/useragent?func=synergy&
&synergyAction=showAbstract&doi=10.1046/j.1468-2982.2002.00394.x

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.